Parkinson Disease Psychosis
Conditions
Brief summary
To examine the current disease progression of PDP, the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers
Interventions
OTHERReal-world, non-interventional
N/A - non-interventional
Sponsors
ACADIA Pharmaceuticals Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adult males and females ≥ 18 with PDP 2. Ability to understand and read English 3. Patient is willing and able to sign an Informed Consent Form (ICF), or have a Legally Authorized Representative willing and able to consent on the patient's behalf 4. Possess the symptoms commonly associated with PDP, e.g., hallucinations and delusions that cannot be reasonably attributed to other causes
Exclusion criteria
1. Patient is unwilling to participate in the non-interventional study 2. Patient is currently participating in or is planning to participate in an investigational clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The INSYTE (Management of Parkinson's Disease Psychosis in Actual Practice) | Approximately 36 months | Describe the safety and effectiveness of antipsychotic therapies and other treatment approaches in the management of PDP. Describe comparative clinical, economic, and humanistic outcomes of treatment approaches for both patients and caregivers, in the context of real-world medical practice settings. |
Countries
United States
Outcome results
None listed